Foundayo (orforglipron), Eli Lilly's daily GLP-1 weight-loss pill, has been approved for use in Australia and should be in pharmacies within days.[1][2] It is a private prescription only, not on the PBS, and newsGP reports Lilly's recommended retail price as about $250 a month for the lower doses and $370 for the higher doses, with each pharmacy free to set its own price.[1][4] Unlike the Wegovy pill, approved two weeks earlier, it can be taken at any time of day with no food or water rules.[1][2][3]
| Medicine | Orforglipron, a daily GLP-1 tablet[1][2] |
|---|---|
| Maker | Eli Lilly[1][2] |
| Approved for | Weight management and type 2 diabetes[1][3] |
| Announced | 17 November 2026[1][2] |
| In pharmacies | "In the coming days"[1][3] |
| Doses | 0.8 mg up to 17.2 mg a day[1][3] |
| Price (RRP) | About $250 to $370 a month[1][4] |
| PBS | Not listed[1][2][3] |
| Food rules | None[2][3] |
Is Foundayo available in Australia?
Yes, or very nearly. Lilly confirmed on Tuesday 17 November that orforglipron, sold as Foundayo, is now on the Australian Register of Therapeutic Goods, and said it would be ready for prescriptions "in the coming days".[1] 7NEWS also reported that the pill is expected within days of the Therapeutic Goods Administration's decision.[2]
Scripts can be filled at a community pharmacy or through LillyDirect, Lilly's own platform.[1][3] Lilly Australia's general manager, Dr Manny Simons, said the company's focus now was "on ways to deliver broader access for Australians who may benefit from this new medicine".[2]
So if you search for Foundayo at your local chemist this week, the honest answer is that stock is on its way, not guaranteed on the shelf. Ring ahead before you take a script in.
How much does Foundayo cost in Australia?
According to newsGP, the RACGP's news service, Lilly has listed recommended retail prices of $250 for a 30-tablet pack of the three smaller doses and $370 for the two higher doses.[1] YourLifeChoices gives the same $250 to $370 a month range.[4] One tablet is taken a day, so a 30-tablet pack is roughly one month of treatment.[1][3]
Two points matter before you budget for it. First, Lilly notes that each pharmacy sets its own price, so the figure on your receipt may be higher or lower.[1] Second, at least one Australian guide published on Tuesday says Lilly has not formally announced an Australian price, so treat these numbers as a guide until your pharmacy quotes you.[3]
For comparison, Lilly's US self-pay price through LillyDirect starts at $149 (US dollars) a month for people paying out of pocket.[8][9] RACGP President Dr Michael Wright told newsGP the Australian cost "looks like" it is lower than the injectable medicines, but warned of "an equity issue" while these drugs are only available privately.[1]
Is Foundayo on the PBS?
No. Foundayo is a private prescription and has not been added to the Pharmaceutical Benefits Scheme.[1][2][3] newsGP reports that neither of the two oral GLP-1 tablets now approved in Australia has yet been recommended for PBS listing by the Pharmaceutical Benefits Advisory Committee.[1] That means you pay the full price, with no PBS co-payment and no concession rate.
Who can be prescribed Foundayo?
The TGA has approved orforglipron for adults in three groups, in each case alongside a healthy diet and more physical activity:[1][3]
- adults with obesity and a starting BMI of 30 or more;
- adults with a BMI of 27 or more who also have at least one weight-related condition, such as high blood pressure, abnormal cholesterol, prediabetes, type 2 diabetes, obstructive sleep apnoea or heart disease;
- people with type 2 diabetes, including those who cannot take metformin, on its own or added to other diabetes medicines.
Lilly says Foundayo should not be used with other GLP-1 medicines, should not be used in pregnancy, and can interact with some other drugs.[2][3] The most common side effects are digestive, such as nausea, and Lilly says they were mostly mild or moderate in trials and more common while the dose was being increased.[1][2]
How do you take it?
Foundayo is one tablet a day, and the main selling point is that it can be taken at any time, with or without food or water.[2][3] RACGP's Dr Wright explained the difference: "It's a small molecule medication, not a peptide, and this means it's better absorbed orally and not breaking down in the stomach."[1]
It comes in six strengths from 0.8 mg to 17.2 mg.[1] Treatment starts on the lowest dose for at least a month and is stepped up over time, with 17.2 mg the highest daily dose if your doctor thinks it is needed.[3]
How well does it work?
In Lilly's main phase 3 trial, published in the New England Journal of Medicine, people taking orforglipron lost up to 12.4% of their body weight over 72 weeks.[1][3] newsGP notes that this result related to a 36 mg dose, higher than the top 17.2 mg strength approved here, and Men's Fitness Australia notes it was measured among people who kept taking the pill.[1][3] Between 5.3% and 10.3% of people on orforglipron stopped treatment, compared with 2.7% on placebo.[1]
That is less than people usually lose on the strongest injections, so the pill is best seen as another option rather than a straight upgrade. Dr Wright put it this way: GLP-1 medicines "can be well tolerated, they're effective, but they're not for everyone".[1]
Foundayo vs the Wegovy pill in Australia
Australia now has two approved GLP-1 weight-loss tablets. Novo Nordisk's Wegovy pill (oral semaglutide) was added to the register on 3 November in 1.5 mg, 4 mg, 9 mg and 25 mg strengths.[5][6][7] Novo Nordisk has said it expects the Wegovy pill to be available before the end of the year, but it has not set a firm launch date or an Australian price.[5][6]
The practical differences, from the sources we checked:
| Item | Foundayo | Wegovy pill |
|---|---|---|
| Maker | Eli Lilly[1] | Novo Nordisk[6] |
| TGA approval | Announced 17 November 2026[1][2] | 3 November 2026[5][6] |
| On sale | Within days[1][2] | Before the end of 2026, no firm date[6][7] |
| Price | RRP about $250 to $370 a month[1][4] | Not announced[5][6] |
| How to take | Any time, no food or water rules[2][3] | Empty stomach, in the morning[1][7] |
| Strengths | Six, 0.8 mg to 17.2 mg[1] | Four, 1.5 mg to 25 mg[5][6] |
| PBS for weight loss | No[1][3] | No[5][6] |
Our read: if you want a tablet now, Foundayo is the one you can actually buy first, and it is the simpler one to take. If you are happy to wait, the Wegovy pill's Australian price is the number to watch, because no one can compare the two on cost until Novo Nordisk names it.
Safety note
Like other GLP-1 medicines, Foundayo carries warnings. Lilly lists low blood sugar when used with insulin or a sulfonylurea, and pancreatitis.[2] Regulators are also watching a rare eye condition, NAION, linked to semaglutide-type drugs; The Nightly reports that the TGA issued a safety warning about it this year.[7] We covered the US label change in our brief on the FDA GLP-1 eye warning.
Buy only on a real prescription from an Australian pharmacy or LillyDirect. Pills sold online without a script are not the approved product.
Frequently asked questions
When will Foundayo be available in Australia?
Lilly says it will be ready to prescribe in the coming days after the 17 November announcement.[1][2]
How much is Foundayo in Australia?
Lilly's recommended retail prices are about $250 a month for lower doses and $370 for higher doses, as reported by newsGP; pharmacies set their own prices.[1][4]
Is Foundayo on the PBS?
No, it is private prescription only.[1][3]
Do I need a prescription?
Yes. It is a prescription medicine, filled at a pharmacy or through LillyDirect.[1][3]
Can I take Foundayo with food?
Yes. It has no food or water restrictions and can be taken at any time of day.[2][3]
Is Foundayo better than the Wegovy pill?
They have not been compared head to head. Foundayo is easier to take and arrives first; the Wegovy pill has no Australian price yet.[1][3][6]
References
- "New oral GLP-1 to hit Australian shelves within days". newsGP, Royal Australian College of General Practitioners. 17 November 2026. Retrieved 17 November 2026.
- "TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian use". 7NEWS. 17 November 2026. Retrieved 17 November 2026.
- "Foundayo in Australia: the GLP-1 pill with no food rules". Men's Fitness Australia. 17 November 2026. Retrieved 17 November 2026.
- "New weight-loss pill approved in Australia without strict mealtime rules". YourLifeChoices. November 2026. Retrieved 17 November 2026.
- "New GLP-1 RA weight-loss tablet approved in Australia". Australian Pharmacist (Pharmaceutical Society of Australia). 4 November 2026, updated 12 November 2026. Retrieved 17 November 2026.
- "First weight-loss tablet approved for use in Australia". InDaily (AAP). 4 November 2026. Retrieved 17 November 2026.
- "TGA approves new form of weightloss medicine Wegovy pill, with daily pill set to be available before Christmas". The Nightly. November 2026. Retrieved 17 November 2026.
- "FDA approval of Eli Lilly's weight-loss pill Foundayo could expand access to GLP-1s". PhillyVoice. April 2026. Retrieved 17 November 2026.
- "Eli Lilly: Foundayo will be available via LillyDirect starting at $25/month with commercial coverage and $149 for self-pay". MarketScreener. April 2026. Retrieved 17 November 2026.